Xencor Inc (XNCR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $24.72 (+0.53%), Market cap $0.94B, 52-week low–high $7.00 ~ $18.14.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinica
Financial statements, price targets, institutional (13F) holdings and related news for Xencor Inc are updated in real time on BlackAll Trade.
Xencor Inc trades at $24.72 (+0.53%). Real-time quotes and charts are available on BlackAll Trade.
Xencor Inc has a market cap of about $0.94B.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ul